The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•26 March 2026•

1 min read

Precigen (PGEN) Sees Over 50% Upside Potential on Strong Papzimeos Launch

Fortified uniQure building, fences, caution tape, security cameras. FDA buildings, US flags, justice symbols. Charts on tablets and papers.

Key Facts

1Precigen (PGEN) maintains a Buy rating with Q1 revenues expected to exceed $18M.

2Management guides for cash flow breakeven in 2026.

Precigen (PGEN) is maintaining a Buy rating following the successful commercial launch of its FDA-approved drug, Papzimeos. Management expects first-quarter revenues to exceed $18 million, driven by robust payer acceptance and strong market demand. This positive momentum has led to a revised financial outlook, with the company guiding for cash flow breakeven by 2026. Scenario analysis suggests a fair value for the stock between $6.13 and $7.01, representing a potential upside of more than 50% from current levels. The successful rollout of Papzimeos is seen as a critical catalyst for the company's long-term growth and valuation. Investors are closely monitoring the company's ability to maintain this revenue run rate as it moves toward profitability.